Apogee (APGE) CMO sells 5,110 shares at $39.8 average

Rhea-AI Filing Summary

Apogee Therapeutics (APGE) filed a Form 4 for its Chief Medical Officer. On 10/01/2025, the officer exercised 2,385 stock options at $22.86 and sold 5,110 shares at a weighted average price of $39.8 pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024.

Following these transactions, beneficial ownership stood at 284,733 shares held directly. Derivative holdings included 161,625 stock options remaining. The option referenced represents the right to purchase 175,345 shares, vesting in forty-eight equal monthly installments through December 18, 2027.

Insider Trade Summary

Net Seller: 5,110 shares ($203,378)

Net Sell 3 txns

Insider Dambkowski Carl

Role Chief Medical Officer

Sold 5,110 shs ($203K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	2,385	$0.00	--
Exercise	Common Stock	2,385	$22.86	$55K
Sale	Common Stock	5,110	$39.80	$203K

Holdings After Transaction: Stock Option (Right to Buy) — 161,625 shares (Direct); Common Stock — 289,843 shares (Direct)

Footnotes (1)

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.33 to $40.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dambkowski Carl

(Last) (First) (Middle)

C/O APOGEE THERAPEUTICS, INC.

221 CRESCENT ST., BLDG. 17, STE. 102B

(Street)

WALTHAM MA 02453

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Apogee Therapeutics, Inc. [ APGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/01/2025		M		2,385	A	$22.86	289,843	D
Common Stock	10/01/2025		S(1)		5,110	D	$39.8(2)	284,733	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$22.86	10/01/2025		M			2,385	(3)	12/18/2033	Common Stock	2,385	$0.00	161,625	D

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024.

2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.33 to $40.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

3. This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer.

	/s/ Matthew Batters, as attorney-in-fact for Carl Dambkowski	10/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Apogee Therapeutics (APGE) disclose in this Form 4?

The CMO exercised 2,385 options at $22.86 and sold 5,110 shares at a weighted average price of $39.8 on 10/01/2025.

Was the APGE insider sale under a trading plan?

Yes. The sale was executed under a Rule 10b5-1 trading plan adopted on August 21, 2024.

How many APGE shares did the officer own after the transactions?

Beneficial ownership was 284,733 shares directly after the reported transactions.

How many derivative securities remain for the APGE officer?

161,625 stock options remained beneficially owned following the transactions.

What is the vesting schedule for the referenced APGE option grant?

It covers 175,345 shares and vests in forty-eight equal monthly installments through December 18, 2027.

What prices were involved in the APGE transactions?

Options were exercised at $22.86; shares were sold at a weighted average price of $39.8, with trades ranging from $39.33 to $40.04.